Inventor · disambiguated record
Elai Davicioni
Also filed as: DAVICIONI ELAI
15 granted patents·22 pending applications·178 citations·filing 2009–2025
93Inventor score
Files withDECIPHER BIOSCIENCES INC14GENOMEDX BIOSCIENCES INC9VERACYTE SD INC6DAVICIONI ELAI3VERACYTE INC3
Top patents by PatentIndex Score
37 records- 0194US10422009B2Compositions and methods for classifying thyroid nodule diseaseGENOMEDX BIOSCIENCES INC·Filed 2017·Granted Sep 24, 2019·19 cites·18 claims
- 0294US9714452B2Compositions and methods for classifying thyroid nodule diseaseGENOMEDX BIOSCIENCES INC·Filed 2015·Granted Jul 25, 2017·24 cites·15 claims
- 0394US9617604B2Systems and methods for expression-based classification of thyroid tissueGENOMEDX BIOSCIENCES INC·Filed 2015·Granted Apr 11, 2017·27 cites·11 claims
- 0493US9206482B2Systems and methods for expression-based classification of thyroid tissueDAVICIONI ELAI·Filed 2010·Granted Dec 8, 2015·27 cites·14 claims
- 0593US9074258B2Compositions and methods for classifying thyroid nodule diseaseDAVICIONI ELAI·Filed 2010·Granted Jul 7, 2015·27 cites·17 claims
- 0691US10865452B2Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancerDECIPHER BIOSCIENCES INC·Filed 2016·Granted Dec 15, 2020·7 cites·14 claims
- 0788US9994907B2Thyroid cancer diagnosticsGENOMEDX BIOSCIENCES INC·Filed 2013·Granted Jun 12, 2018·23 cites·11 claims
- 0887US10513737B2Cancer diagnostics using non-coding transcriptsDECIPHER BIOSCIENCES INC·Filed 2012·Granted Dec 24, 2019·9 cites·7 claims
- 0984US11208697B2Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 28, 2021·5 cites·11 claims
- 1084US11078542B2Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2018·Granted Aug 3, 2021·3 cites·3 claims
- 1182US11414708B2Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyDECIPHER BIOSCIENCES INC·Filed 2017·Granted Aug 16, 2022·3 cites·9 claims
- 1279US2025171854A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessVERACYTE INC·Filed 2024·Application pending·0 cites
- 1377US2025327136A1Systems and methods for preprocessing target data and generating predictions using a machine learning modelVERACYTE SD INC·Filed 2025·Application pending·0 cites
- 1474US2024417800A1Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancerVERACYTE INC·Filed 2024·Application pending·0 cites
- 1571US12378610B2Systems and methods for preprocessing target data and generating predictions using a machine learning modelVERACYTE SD INC·Filed 2023·Granted Aug 5, 2025·0 cites·19 claims
- 1668US2024360517A1Subtyping prostate cancer to predict response to hormone therapyVERACYTE SD INC·Filed 2024·Application pending·0 cites
- 1767US2022349011A1Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1866US11035005B2Cancer diagnostics using biomarkersDECIPHER BIOSCIENCES INC·Filed 2013·Granted Jun 15, 2021·4 cites·14 claims
- 1966US2022177974A1Genetic signatures to predict prostate cancer metastasis and identify tumor aggressivenessDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2065US2022325352A1Molecular subtyping, prognosis, and treatment of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2164US2023220485A1Cancer biomarkers and classifiers and uses thereofVERACYTE SD INC·Filed 2022·Application pending·0 cites
- 2264US2025308632A1Prognosis and treatment of molecular subtypes of prostate cancerVERACYTE INC·Filed 2023·Application pending·0 cites
- 2362US2023151429A1Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapyVERACYTE SD INC·Filed 2022·Application pending·0 cites
- 2460US2016032395A1Cancer biomarkers and classifiers and uses thereofDAVICIONI ELAI·Filed 2014·Application pending·0 cites
- 2560US2011136683A1Systems and Methods for Expression-Based Discrimination of Distinct Clinical Disease States in Prostate CancerGENOMEDX BIOSCIENCES INC·Filed 2009·Application pending·0 cites
- 2659US2018030540A1Systems and Methods for Expression-Based Classification of Thyroid TissueGENOMEDX BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 2759US2024002944A1Methods and genomic classifiers for identifying homologous recombination deficiency prostate cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2857US2024319192A1Use of immune content scores diagnostically to predict responsiveness of prostate cancer patients to immunotherapyDECIPHER BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2954US2019100805A1Thyroid cancer diagnosticsGENOMEDX BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 3054US2023115828A1Genomic classifiers for prognosing and treating clinically aggressive luminal bladder cancerDECIPHER BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3153US11873532B2Subtyping prostate cancer to predict response to hormone therapyVERACYTE SD INC·Filed 2018·Granted Jan 16, 2024·0 cites·10 claims
- 3251US2022213557A1Non-coding rna for subtyping of bladder cancerDECIPHER BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3350US2018291459A1Use of a genetic signature diagnostically to evaluate treatment strategies for prostate cancerGENOMEDX BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 3446US2016258026A1Cancer biomarkers and classifiers and uses thereofUNIV BRITISH COLUMBIA·Filed 2014·Application pending·0 cites
- 3545US12497660B2Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapyDECIPHER BIOSCIENCES INC·Filed 2018·Granted Dec 16, 2025·0 cites·19 claims
- 3639US2022033912A1Transcriptomic profiling for prognosis of breast cancer to identify subjects who may be spared adjuvant systemic therapyPFS GENOMICS INC·Filed 2019·Application pending·0 cites
- 3734US2019204322A1Molecular subtyping, prognosis and treatment of prostate cancerGENOMEDX BIOSCIENCES INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elai Davicioni files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →